Thamm K, Njau F, Van Slyke P, Dumont DJ, Park JK, Haller H, David S. World J Transplant. 2016 Sep 24;6(3):573-82. doi: 10.5500/wjt.v6.i3.573. PMID: 27683636
Thamm K, Njau F, Van Slyke P, Dumont DJ, Park JK, Haller H, David S. World J Transplant. 2016 Sep 24;6(3):573-82. doi: 10.5500/wjt.v6.i3.573. PMID: 27683636
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.